Yuanda Pharmaceutical (00512) rose more than 5% in early trading, and climbed about 15% after the results. As of press release, it rose 5.06% to HK$4.15, with a turnover of HK$8.2581 million.
The Zhitong Finance App learned that Yuanda Pharmaceutical (00512) rose more than 5% in early trading, and increased by about 15% after the results. As of press release, it rose 5.06% to HK$4.15, with a turnover of HK$8.2581 million.
According to the news, Yuanda Pharmaceutical announced that the Group's globally innovative radionuclide conjugate drug (RDC) ITM-11 for the treatment of gastrointestinal and pancreatic neuroendocrine tumors has recently been approved by the China Drug Administration to carry out phase III clinical research. According to the group, the study plans to enroll at least 202 patients in 11 countries around the world, including China, the United States, the United Kingdom, France, Germany, and Australia.
It is worth noting that Yuanda Pharmaceutical recently announced its 2023 annual results. The company recorded annual revenue of about HK$10.53 billion, an increase of 15.8% year over year; gross profit of about HK$6.52 billion, up 15.3% year on year before exchanging exchange rate effects; net profit from normalization was about HK$2.04 billion, up 0.2% year on year before exchange rate effects were excluded. The board of directors recommended a dividend of HK26 cents per share, with a total dividend of about HK$910 million. It has been distributed continuously for 6 years, with a cumulative dividend of approximately HK$2.8 billion.